About Regulatory News

Regulatory News reports on the regulatory developments affecting pharmaceutical, biotech, and medical device organizations — FDA, EMA, MHRA, EU MDR and IVDR, and ICH. It launched on 15 July 2026.

The premise is narrow on purpose. Regulatory professionals are not short of commentary; they are short of time, and short of anyone willing to read the actual instrument and say plainly what it does and does not say. Most of what circulates as regulatory news is a summary of a summary, and the compression is where the errors live.

Editorial standards

  • Sourced to the primary record. Every factual claim links to the document it comes from — the Official Journal, the Federal Register, the guidance PDF — and not to another outlet’s write-up of it.
  • The fact, then the meaning, then the caveat. What changed comes first. What it means comes second. What is still unresolved is stated rather than smoothed over.
  • We say when it is unknown. A well-drawn boundary around what has not been decided is more useful than a confident guess, and we would rather publish the boundary.
  • Reporting and advice are different things. News reports what happened. Anything arguing for a course of action is labelled Analysis. You should always know which you are reading.
  • Named bylines. A person is accountable for every story.
  • Dates are load-bearing. Every story carries a publish date and an honest modified date, because readers act on this material.

Corrections

When we get something wrong, we append the correction to the story, dated, and list it on the corrections page. We do not silently edit a published story to make an error disappear. A publication that quietly rewrites its record has nothing left worth reading.

Who publishes this

Regulatory News is published by Regulatory Leadership Partners, a firm that places senior regulatory and quality leaders into pharma, biotech, and medical device organizations.

Why we tell you that up front. A regulatory reader who works out on their own that an outlet belongs to a consultancy discounts everything it has ever published — and they are right to. The disclosure is not a legal formality; it is the only basis on which the reporting is worth anything.

So, concretely: stories are chosen by what a regulatory professional needs to know, not by what the publisher sells. Articles do not pitch services, and the link at the end of a story invites you to read another story. Where a subject touches the publisher’s commercial interests, that is a reason for more care, not less.

Contact

Corrections, tips, and complaints: editor@regulatorynews.com. Corrections get read first.